{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-038730","form_type":"8-K","ticker":"CNTN","cik":"0001861657","company_name":"Canton Strategic Holdings, Inc.","filed_at":"2024-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.994632+00:00","generated_at":"2026-05-31T00:54:11.426722+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tharimmune signs nonbinding LOI to merge with Intract Pharma; 49% stake for Intract shareholders","bullets":["Tharimmune and Intract Pharma entered nonbinding LOI; Tharimmune to acquire Intract for restricted stock.","Intract shareholders will own 49% of combined entity; merger expected to close in Q1 2025.","Combined company will leverage Intract's Soteria and Phloral oral delivery platforms for biologics.","Existing license for oral anti-TNF antibody (INT-023/TH023) from Intract remains unaffected.","Transaction aims to expand Tharimmune's pipeline in inflammation and immunology."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-038730","json":"https://secwatch.observer/filing/0001493152-24-038730.json","markdown":"https://secwatch.observer/filing/0001493152-24-038730.md","text":"https://secwatch.observer/filing/0001493152-24-038730.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861657/000149315224038730/0001493152-24-038730-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861657/000149315224038730/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T00:54:11.426722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}